Expert Sees Need for Better Guideline Adherence in NSCLC
January 19th 2021At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.
Markman: COVID-19 Takes Science on a Roller-Coaster Ride
January 10th 2021In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.
Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL
January 8th 2021Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
Next-Generation Cytotoxic Therapy Moves Forward in mCRPC
January 7th 2021VERU-111, a next-generation form of chemotherapy, has shown promising signs of efficacy as a treatment option for men with metastatic castration-resistant prostate cancer whose disease has progressed while receiving androgen receptor–targeting therapy.